Irccs Istituto Ortopedico Rizzoli
Bologna, Emilia-Romagna, 40136, Italy
Location status: Recruiting
Location contact
Luca Sangiorgi, PhD
PRINCIPAL_INVESTIGATOR
Marcella Lanza, PhD
CONTACT
Marina Mordenti, PhD
CONTACT
NCT Number: NCT05247645
RD-DATA is a retrospective and prospective data collection, finalized for care and research purposes. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc.
This approach has been developed to corroborate and integrate data from different sources and evaluating several aspects of the diseases and to correlate genetic background and phenotypic outcomes, in order to better investigate diseases pathophysiology. Due to legal requirements, institutional directives and organizational issues, we are unable to include individuals residing outside Italy in the registry at this time. We are currently engaged in the preparation of a recruitment process for individuals residing outside Italy.
Interested in participating?
Request InfoAll sexes
Observational
Bologna, Emilia-Romagna, 40136, Italy
Location status: Recruiting
Luca Sangiorgi, PhD
PRINCIPAL_INVESTIGATOR
Marcella Lanza, PhD
CONTACT
Marina Mordenti, PhD
CONTACT
The traditional method of collecting patient information is frequently chaotic, inconvenient and sometimes even unsafe, particularly when dealing with rare diseases. In 2020, the need to simplify the diagnostic process and to overcome the difficulties of data storage and analysis, led to the suggestion of implementing the Data Collection of Patients With Rare Bone Diseases - RD-DATA.
The RD-DATA relies on an IT platform named Genotype-phenotype Data Integration platform (GeDI).This solution, realized by a collaboration among Rare Skeletal Disorders Department and a local software-house (Dilaxia Spa) is a General Data Protection Regulation (GDPR)-compliant, multi-client, web-accessible system and it has been designed according to current medical informatics standards (Orphanet code, ICD-10 (International Disease Classification), Human Genome Variants Society). GeDI is continuously implemented to improve management of persons with rare conditions with predominantly skeletal involvement and to help researchers in analysing collected information. RD-DATA is articulated in main sections:
Personal data: it comprises general information, birth details and residence data; Patient data: including the patients internal code, the hospital code and other details on patients; Diagnostic Process: the diagnosis, the status (affected, suspected, etc.), age at diagnosis, comorbidities, allergies, etc.; Genogram: a tool for designing family transmission of the disease, alongside information on the diseases status of all relatives included.
Clinical events: it records a long list of signs and symptoms as well as several additional items to describe the disease Genetic Analysis and Alteration: including technique, sample information, analysis duration, etc. In addition, this section comprises detailed information on detected pathological variants (gene, international reference, DNA change, Protein change, genomic position, etc.).
Visits: it includes the typology of the visit (genetic, orthopedic, rehabilitation, pediatric, etc.), the date of the visit, treatment, prescription, imaging, etc.
Treatments: this section comprises information of a wide range of treatments including pharmacological, devices, supplements, and other treatments such as psychological, nutritional, etc.; Documents: this repository allow us to store all types of documents (radiological reports, imaging, consents, clinical reports, etc.); Consents: this section provides a comprehensive overview of all consents collected, including the collection date; Samples: this section includes information on the samples, like the type, date of collection, etc.; PROs: this section collects information on patients reported outcomes such as the quality of life or ABC scale.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Since the disease is rare, the timeframe is strictly related to patients enrolment and consequently to amount of collected data. A 10 years period will probably answer general issues.
To maintain an established registry in order to assess epidemiology and natural history.
Collection of:
Clinical, orthopedic and functional features are updated at each follow up. Clinical reports, medical charts and imaging are the primary sources of data.
Time frame: 25 years
The secondary outcome comprises the correlation between genotype and phenotype. This includes but is not limited to clinical features and genetic background. This will be pursued using the information collected during visits and follow-ups and the genetic information resulting from molecular investigations, when available.
Time frame: 25 years
This outcome aims to investigate the evolution of the diseases. Main clinical features, such as height (cm), number and localization of signs and symptoms, number and localization of deformities, number and localization of limitations will be collected both retrospectively and prospectively in the entire population via physical examination, clinical reports and imaging.
An evaluation of these parameters will be performed at each visit to keep track on the progression of the clinical manifestations.
Contact information is provided by the study sponsor or research team.
Marcella Lanza, PhD
CONTACT
Marina Mordenti, PhD
CONTACT
Luca Sangiorgi
Other
Structured Collection of Data Relating to Rare Diseases With Predominantly Skeletal Involvement
Acronym: RD-DATA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05876416
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Stockholm, Sweden
View Trial DetailsNCT03548779
Autism Spectrum Disorder, Brain Diseases
Asheville, North Carolina, United States
View Trial DetailsNCT05991609
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bath, United Kingdom
View Trial DetailsNCT05031507
Bone Diseases, Bone Diseases, Developmental
Bethesda, Maryland, United States
View Trial Details